AQST Q2 2025 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AQSTAquestive Therapeutics, Inc.

$431M

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$10M-50.2% YoY

Gross Profit

$5M54.4% margin

Operating Income

-$11M-113.6% margin

Net Income

-$14M-135.4% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

+14.7%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$94M

Total Liabilities

$166M

Stockholders' Equity

-$73M

Cash & Equivalents

$61M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$20M	-50.2%
Gross Profit	$5M	$16M	-65.1%
Operating Income	-$11M	$55,000	-20769.1%
Net Income	-$14M	-$3M	-393.6%

Revenue Segments

Manufacture and Supply Revenue

$10M89%

License and Royalty Revenue

$839,0008%

Co-Development and Research Fees

$378,0004%

Geographic Segments

Non-US

$5M51%

UNITED STATES

$5M49%